MAPTO Survey Reveals Global Variability in Managing FVIII Inhibitors in Children on Emicizumab – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Lilianne van Stam et al, adding:
”The MAPTO Survey: Worldwide Approaches on Unmasking Factor VIII Inhibitors in Children with Emicizumab Treatment
A global survey of 102 healthcare providers across 38 countries reveals highly heterogeneous practices regarding FVIII inhibitor risk assessment and concomitant FVIII use in previously untreated hemophilia A children on emicizumab, underscoring the urgent need for evidence-based treatment guidelines.”
Title: The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders
Authors: Lilianne van Stam, Bridget Horstman, Pantep Angchaisuksiri, Manuel Carcao, Gili Kenet, Christoph Königs, Johnny Mahlangu, Maria Mancuso, Suely Rezende, Robert Sidonio, Alok Srivastava, Guy Young, Karin Fijnvandraat, Samantha Gouw
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 4, 2026, 00:33Ashish Pemawat: Can We Protect the Brain while We Restore Blood Flow?
-
Oct 4, 2026, 00:32Marta Nowakowska-Kotas: Could a Small Rise in Creatinine after Thrombectomy in Stroke Patients Be an Early Warning Sign?
-
Oct 4, 2026, 00:26Mohammad Nafeli Shahrestani: CXCL10 Associated With Increased Long-Term Risk of Ischemic Stroke
-
Oct 4, 2026, 00:23Asim Katbeh: Light Spot on the Spectrum of Ischemic Heart Disease in Women
-
Oct 3, 2026, 17:26Karel Kostev։ When First Anticoagulant Prescriptions Are Not Dispensed
-
Oct 3, 2026, 17:11Nabila Hasan: Thalassemia Awareness And Prevention
-
Oct 3, 2026, 17:03Pasinee Sangsiwarit: Neutrophil Dysfunction In β-Thalassemia
-
Oct 3, 2026, 16:18Mira Kassouf: Reactivating An Embryonic Gene To Treat α-Thalassemia
-
Oct 3, 2026, 15:49Behnood Bikdeli: COATED_AIR Trial Design Published as Enrollment Reaches 3,000 Patients